Medicinal cannabis shares crash lower

With the local market following the lead of US markets and sinking lower today, a good number of sectors have sunk into the red.

One area of the market which has fallen more than most is the medicinal cannabis industry.

Here is the state of play in the industry at the moment:

  • The Auscann Group Holdings Ltd (ASX: AC8) share price has fallen almost 3% to $1.61
  • The Cann Group Ltd (ASX: CAN) share price is down 4.5% to $3.12.
  • The Creso Pharma Ltd (ASX: CPH) share price is lower by 4% to 99 cents.
  • The Hydroponics Company Ltd (ASX: THC) share price is down 3.5% to 82 cents.
  • The MGC Pharmaceuticals Ltd (ASX: MXC) share price is off 4% to 11.5 cents.
  • The MMJ Phytotech Ltd (ASX: MMJ) share price has dropped 3% to 50.5 cents.

What happened?

While Cann Group’s decline could be related to its quarterly update released this morning, I think the main catalysts for these declines have been a combination of profit taking and investors going into risk-off mode following a sizeable drop in US equities.

After all, Australian medicinal cannabis shares have been some of the biggest movers on the market since the start of the year. The AusCann share price, for example, has more than doubled in value in 2018 even after a series of notable declines over the last few days.

And with so much future growth built into their shares already, they certainly are some of the most high risk shares on the market.

Should you buy the dip?

While one of two of these shares could go on to have extremely bright futures, at this stage it is a little hard to know which ones will be the winners and which will be the losers.

So for now, investors may be better off focusing on other areas of the market until it becomes clear just who is going to be the market leader in Australia.

In the meantime, I think these blue chip shares would be great options for investors in 2018 and expect them to beat the market.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.